The abstract is read at the publisher; the summary is JClub's.
In 31 patients with advanced sarcoma receiving MASCT-I maintenance after first-line chemotherapy, median PFS1 was 9.5 months and median OS was 33.8 months after 63.6 months follow-up.
- Why it matters: Advanced sarcomas often have limited maintenance options once initial chemotherapy ends, leaving a gap in durable disease control and long-term immune support.
- What they did: In a multicenter phase I trial (NCT03034304), patients with disease control received MASCT-I alone (n = 17) or with ifosfamide (n = 14), with safety as the primary endpoint and PFS/OS plus antigen-specific immune analyses as secondary/exploratory measures.
- The result: MASCT-I was well tolerated with no treatment-related deaths; high antigen-specific immunity was significantly positively associated with prolonged survival, and 6 of 7 patients progression-free for over 4 years showed robust immune activation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.